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a b s t r a c t
The aim of this study was to evaluate a flat rectangular (3  10 mm2) MRI compatible transducer oper-
ating at 5 MHz. The main task was to explore the feasibility of creating deep lesions in heart at a depth
of at least 15 mm. The size of thermal necrosis in heart tissue was estimated as a function of power and
time using a simulation model. The system was then tested in an excised lamb heart. In this study, we
were able to create lesions of 15 mm deep with acoustic power of 6 W for an exposure of approximately
1 min. The contrast to noise ratio (CNR) between lesion and heart tissue was evaluated using fast spin
echo (FSE). The CNR value was approximately 22 using T1W FSE. Maximum CNR was achieved with rep-
etition time (TR) between 300 and 800 ms. Using T2W FSE, the corresponding CNR was approximately 13
for the 14 in vivo experiments. The average lesion depth was 11.93 mm with a standard deviation of
0.62 mm. In vivo irradiation conditions were 6 W for 60 s. The size of the lesion in the other two dimen-
sions was close to 3  10 mm2 (size of the transducer element).
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1. Introduction
Arrhythmia is a problem with the speed or rhythm of the heart-
beat. In this condition, the heart can beat too fast, too slow, or with
an irregular rhythm. Most arrhythmias are harmless, but some can
be serious or life threatening. With arrhythmia, the heart may not
be able to pump enough blood to the body [1] Lack of blood flow
can damage the brain, heart, and other organs. Atrial fibrillation
(AF) and Ventricular Fibrillation (VF) are the most common types
of serious arrhythmias.
AF is a very fast and irregular contraction of the atria. AF occurs
when the heart’s electrical signal begins in a different part of the
atrium than the sinoatrial (SA) node or when the signal is con-
ducted abnormally [1–3].
⇑ Corresponding author. Address: 105 Evagora Laniti, 3111 Limassol, Cyprus. Tel.:
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VF occurs when disorganized electrical signals make the ventri-
cles quiver instead of pump normally. Without the ventricles
pumping blood out to the body, a person will lose consciousness
within seconds and will die within minutes if not treated [1] To
prevent death, the condition must be treated immediately with
defibrillation, an electric shock to the heart.
The Cox–Maze procedure is the gold standard for the surgical
treatment of atrial fibrillation (AF) [4–7] Despite its efficacy, this
procedure is not widely performed because of its complexity and
technical difficulty. Recently, the introduction of ablation technol-
ogies has significantly changed this attitude. To simplify the oper-
ation, the incisions of the traditional cut and sew Maze procedure
have been replaced with linear lines of ablation.
Ablation technologies have greatly simplified surgical ap-
proaches and have significantly increased the number of proce-
dures being performed [8]. Various energy sources have been
used clinically, including cryoablation, radiofrequency, microwave,
laser, and high-frequency ultrasound. The goal of these devices is
to create lesions to block activation wavefronts [8].
Cryoablation is unique among presently available technologies
in that it destroys tissue by freezing instead of heating. The biggest
advantage of this technology is its ability to preserve tissue archi-
tecture and collagen structure [9]. The potential disadvantage of
this technology is the relatively long time necessary to create an
ablation lesion (2–3 min). Also, the circulating blood volume acts
as a heat sink which makes creating lesions in the beating heart
difficult [9].
In electrophysiology laboratories, RF energy has been used for
cardiac ablation for many years [10]. It is one of the first energy
sources to be used in the operating room for AF ablation. The first
team to use RF energy in humans was that of Borggrefe et al. [11]
who disconnected a right-sided accessory pathway. Their pioneer-
ing work, which was subsequently been followed by many other
teams, opened the door to transvenous ablation at a significantly
lower risk compared with direct current (DC) ablation. This ren-
dered RF ablation a widely applicable therapy for patients with
supraventricular and ventricular arrhythmias. The efficacy of RF
ablation is limited in cases which require the ablation of larger
areas in thicker tissues, and when ablation is performed on the left
side of the heart the risk of charring and thrombus formation be-
comes an issue, especially when high power settings and high tar-
get temperatures are used. Amajor advance in this area came after a
long series of animal experiments mainly performed by Wittkampf
[12] using irrigated tip RF ablation with closed or open irrigation.
Microwave ablation is an interesting technology that has sev-
eral advantages over RF [13]. It is less likely to create char forma-
tion and is less sensitive to electrode positioning. It can reliably
create transmural endocardial lesions, but it is not capable of cre-
ating epicardial lesions on the beating heart. Microwave ablation is
an unfocused energy source that can cause collateral injury. This
has been documented in case reports [13].
Laser ablation is a promising technology that may have some
advantages over other energy sources [14–16]. The energy is fo-
cused, unaffected by overlying fat, and uses flexible fiber optics
to deliver the energy to tissue. A disadvantage of this technology
is that the energy delivery is unconfined and thus could cause col-
lateral damage.
Therapeutic ultrasound, is a non-invasive extracorporeal tech-
nique capable of thermally ablating subsurface structures without
injuring intervening tissues. Ultrasonic energy can be applied in a
target volume to induce molecular agitation, absorptive heating,
and ultimately thermal coagulative tissue necrosis. Therapeutic
ultrasound offers several potential advantages over other therapy
modalities. Unlike microwaves, it can be readily focused within
small volumes. It does not have the cumulative risks associated
with ionizing radiation, and it is unaffected by the optical opacities
that block laser penetration. Furthermore, in contrast to radiofre-
quency (RF) waves, therapeutic ultrasound does not require direct
contact with target tissue. The use of therapeutic ultrasound to cre-
ate focal, ablative lesions in the heart has been reported in exper-
imental models [17–19].
Therapeutic ultrasound was explored as a therapeutic modality
in almost every accessible tissue. Several studies have examined
the histological changes related to therapeutic ultrasound ablation
in various tissues [20,19,21,22,18,23–27].
Within the last decade, therapeutic ultrasound has been used in
various in vitro models [28–32]. Okumura et al. in 2008 [31], per-
formed a study to examine tissue temperatures around pulmonary
veins (PVs) during therapeutic ultrasound balloon ablation for at-
rial fibrillation. In 2009, Yokoyama and colleagues [30] developed
a canine model of esophageal injury and left atrial-esophageal fis-
tula after applications of forward-firing therapeutic ultrasound and
side-firing unfocused ultrasound. Neven et al. in 2010 [29], evalu-
ated an esophageal temperature (ET)-guided safety algorithm to
apply therapeutic ultrasound in order to avoid severe complica-
tions with standard ablation of pulmonary vein isolation (PVI).
Therapeutic ultrasound has been used in various in vivo models
for heart applications: Strickberger et al. in 1999 [18], carried out a
study to determine whether therapeutic ultrasound can be used to
ablate the atrioventricular (AV) junction within the beating heart.
Their study suggested that therapeutic ultrasound produced
well-demarcated lesions and appears to be a feasible energy source
to create complete AV block within the beating heart without dam-
aging the overlying or underlying cardiac tissue. Otsuka et al. [33]
investigated the possibility of myocardial ablation in the left ven-
tricle of beating dog hearts by monitoring treatment with 2-
dimensional echocardiography. Recently a transesophageal ultra-
sound applicator was designed and evaluated with in vivo experi-
ments [34,35] for the treatment of atrial fibrillation. The results
indicated a potential application of the transesophageal ultrasound
applicator for atrial fibrillation treatment.
Over the last decade, clinical studies have been conducted using
commercially therapeutic ultrasound systems. Early study [36], re-
vealed that, therapeutic ultrasound can create precise defects in
different cardiac tissue without damage to the surrounding tissue.
A multicenter clinical trial in 2005 [37], showed that after 6-month
follow-up, epicardial, off-pump, beating-heart ablation with acous-
tic energy is safe and cures 80% of patients with permanent atrial
fibrillation associated with long-standing structural heart disease.
A therapeutic ultrasound balloon catheter to isolate pulmonary
veins (PVs) outside the ostia (PV antrum) was designed by Nakag-
awa et al. in 2007 [38]. Results of this study showed that forward-
focused therapeutic ultrasound application isolated PVs outside
the PV ostium with elimination of AF in 16 (59%) of the 27 patients
at 12 months following the single ablation procedure. Another
study by Schmidt et al. in 2009 [39] showed that, the novel defo-
cused 12F Therapeutic Ultrasound-Ballon Catheter used in con-
junction with a steerable sheath allows for very rapid pulmonary
vein isolation (PVI) in patients with paroxysmal atrial fibrillation
(PAF). Epicor cardiac ablation system [40,41] has been proven to
be a concomitant procedure during open heart surgery that is safe
and acceptably effective for the treatment of AF. Metzner et al. in
2010 [42], performed a clinical study for pulmonary vein isolation
using first and second generation therapeutic ultrasound balloon
catheters (ProRhythm, Ronkonkoma, NY, USA). Patients treated
with symptomatic PAF showed long-term success rates similar
radiofrequency current (RFC) ablation-based PVI procedures.
The combination of ultrasound and MRI was first cited by Jolez
and Jakab [43] who demonstrated that an ultrasonic transducer
can be used inside an MRI scanner. The concept of using MRI to
monitor the necrosis produced by therapeutic ultrasound was
demonstrated in the early 90’s by Hynynen et al. [44] in canine
muscle. In the following years many studies have been conducted
[45–50] showing that the contrast between necrotic tissue and
normal tissue was excellent.
In this paper a flat rectangular MRI compatible transducer,
3  10 mm2, operating at a frequency of 5.3 MHz was used [51].
The aim was to create lesions in lamb heart in vitro and in rabbit
in vivo using the cardiac transducer in order to measure the size
of thermal necrosis in relation to the power and time. The experi-
mental results are comparedwith the results of a simulationmodel.
Another task was to investigate the effectiveness of MRI in
monitoring therapeutic protocols of therapeutic ultrasound in the
heart. This was achieved with the optimization of MRI pulse se-
quences in order to maximize contrast between thermal necrosis
and healthy cardiac tissue. Screening with MRI makes therapeutic
ultrasound a more credible way of treatment in comparison to
other ablation methods which are guided by X-rays. MRI offers a
better contrast between thermal necrosis and healthy cardiac tis-
sues, and offers the additional advantage that the patient will not
be exposed to radiation. Therefore we have used the basic MRI se-
quences T1-W and T2-W fast spin echo (FSE). With T1-W FSE, the
effect of repetition time (TR) on contrast was explored, whereas
with T2-W FSE, the effect of echo time (TE) was explored.
The main innovation of this study is the evaluation of a planar
MR compatible transducer in both in vitro and in vivo exploring
the following 2 main issues:
(a) Acquire knowledge regarding the size of the lesion as a func-
tion of power and time (using simulation and experimental
models) which could be used as a preliminary data for future
clinical trials and
(b) Optimize the FSE MRI techniques for detecting the lesions
created in heart tissue.
The advantage of using MRI is that the lesions can be monitored
nearly in real time and therefore unwanted complications similar
to what was reported byMetzner et al. in 2010 [42] can be avoided.
2. Materials and methods
2.1. HIFU/MRI system
Fig. 1 shows the block diagram of the therapeutic ultrasound/
MRI system. The therapeutic ultrasound system consists of a signal
generator (HP 33120A, Agilent technologies, Englewood, CO, USA),
a RF amplifier (250 W, AR, Souderton, PA, USA), and a flat rectangu-
lar MR compatible transducer (Fig. 2).
The transducer consisted of a 3.8-mm outer diameter copper
tube with a 0.1-mm thick wall ending in a cone-shaped MR com-
patible plastic tip. The plane active surface embedded in the plastic
section is a 3  10 mm2 P762-type PZT piezoceramic air-backed
transducer (Quartz & Silice, Nemours, France) operating at
5.3 MHz. In order to heat the myocardium for the purpose of treat-
ing arrhythmias, the transducer must be placed in a catheter. Be-
cause the catheter is guided to the myocardium through the
arteries which are only 3–4 mm wide, the transducer element
must be as compact as possible. If a spherically focused technology
is used, then the size of the transducer will increase and therefore
will not fit in the catheter. Also, because the catheter is inserted
into the body, the catheter is destroyed after treatment (i.e. it is
considered as consumable). Thus, a spherically focused technology
has the additional disadvantage that will increase the cost substan-
tially. Additionally, as it will be seen from the results, a flat trans-
ducer produces lesions of desired size.
The central lumen of the tube provided electrical radiofre-
quency (RF) connections and a path for the cooling water. RF con-
nections were made via a miniaturized 50-cm long, 50X coaxial
cable with a 0.9-mm outer diameter. The outer ground conductor
was connected to the external face of the transducer. The inner
conductor reached the internal face of the transducer through
the lumen of the tube. The transducer was glued with an MR com-
patible epoxy resin (Emerson & Cuming Europe nv, Westerlo-Oe-
vel, Belgium) to ensure that it was watertight and to hold it in
place. To limit energy loss during transmission of the electric sig-
nal, a connection with a capacitor-inductor network was included
to match the transducer. Using the acoustic balance technique by
Signal generator
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Fig. 1. Block diagram of the HIFU/MRI system used to drive the flat rectangular transducer.
Fig. 2. Schematic of the flat rectangular MR compatible transducer.
Davidson 1991 [52], the electroacoustic efficiency of the applicator
was measured to 65% at 5.3 MHz. The external face of the trans-
ducer was cooled by a continuous flow of degassed water circulat-
ing the length of the transducer. The cooling water serves as
coupling medium between the transducer and the heated tissues.
The water cooling circuit was maintained at 15 C and was driven
by a Masterflex peristaltic pump (Cole Parmer Instrument Co., Chi-
cago, IL) at a flow of 0.15 L/min.
2.2. Simulation model
Numerical simulations were performed to predict the shape of
the thermally ablated zone for different strategies, varying the fol-
lowing input parameters: thickness of the cooling water, the ele-
mentary sonication duration and the acoustical power. The
model was proposed by Chavrier et al. 2000 [53] improved later
by Curiel et al. 2004 [54]. It is based on the Bio Heat Transfer Equa-
tion proposed by Pennes [55]. Simulations neglected cavitation as
the evaluated transducer is not focused and operates in the high
frequency range.
The initial temperature of the heart was assumed to be 37 C
and the initial temperature of the water was assumed to be
15 C. The spatial step used during the simulation was 0.5 mm
and the temporal step used during the simulation was 0.1 s. The
thermal dose threshold of necrosis was considered to be 240 min
referenced at 43 C.
The numerical model was implemented in C++ supported by a
graphic user interface developed in MATLAB (MathWorks, Natick,
United States). The simulation environment provided the following
output: a 3D view plus two central sections of the predicted ab-
lated zone, total volume of the coagulation necrosis and 3D map
of estimated thermal dose.
Numerical simulations were performed for some exposures
in vivo conditions (the tissue parameters used are shown in
Table 1).
2.3. Temperature measurement
Temperature was measured using a Digital to analog data
acquisition card (USB 6250, National Instruments, Austin Texas,
USA) and a voltage to temperature converter (Omega Engineering,
Stamford, Connecticut, USA). Temperature is sensed using a 50-lm
diameter T-type copper-constantan thermocouple (Physitemp
Instruments, Inc. New Jersey, USA) which is MRI compatible. The
thermocouple was placed between the tissue and the transducer
surface, thus measuring the temperature at the surface of the tis-
sue. The temperature error of the thermocouple was on the order
of 0.1 C. In all the experiments, the goal was to keep the temper-
ature below 100 C in order to avoid boiling.
2.4. In vitro experiments
Various in vitro experiments were carried out to image the le-
sions using MRI created in cardiac tissue using therapeutic ultra-
sound. The tissue was placed inside the water container which
was filled with degassed water at room temperature. The trans-
ducer was coupled to the holder and was immersed in the water
tank, thus providing good acoustical coupling between tissue and
transducer (see Fig. 1 for the experimental arrangement). In all
experiments, the tissues used were extracted from freshly excised
lamb, and the experiment was conducted in the same day. In total,
18 samples were used.
2.5. In vivo experiments
For the in vivo experiments, adult rabbits from Cyprus were
used weighting approximately 3–4 kg. 14 rabbits in total were
used in the experiments. The rabbits were anaesthetized using a
mixture of 500 mg of Ketamine (100 mg/mL, Aveco, Ford Dodge,
IA), 160 mg of Xylazine (20 mg/mL, Loyd Laboratories, Shenan-
doah, IA), and 20 mg of Acepromazine (10 mg/mL, Aveco, Ford
Dodge, IA) at a dose of 1 mL/kg. The protocol for the animal exper-
iments was approved by the national body in Cyprus responsible
for animal studies (Ministry of Agriculture, Animal Services).
2.6. MRI processing
An MRI scanner (Signa 1.5 T, by General Electric, Fairfield, CT,
USA) was used. The ultrasound transducer is coupled to the holder.
The spinal coil (USA instruments, Cleveland, OH, USA) was used to
acquire the MR.
The following parameters were used for T1-W FSE: TR was var-
iable from 100 to 1000 ms, TE = 9 ms, slice thickness = 3 mm (gap
0.3 mm), matrix = 256  256, FOV = 16 cm, NEX = 1, and ETL = 8.
For T2-W FSE: TR = 2500 ms, TE was variable from 10 ms to
160 ms, slice thickness = 3 mm (gap 0.3 mm), matrix = 256  256,
FOV = 16 cm, NEX = 1, and ETL = 8.
The CNR was obtained by dividing the signal intensity differ-
ence between the Region of Interest (ROI) in the lesion and in
the ROI of normal tissue by the standard deviation of the noise in
the ROI of normal tissue. The ROI was circular with diameter of
3 mm.
3. Results
Fig. 3 shows T1W FSE images of the 2 transducers utilized dur-
ing the experiments in sagittal (Fig. 3A) and coronal (Fig. 3B)
planes. Note the RF artefacts of the transducers are minimal. There
is a 1 mm artefact around the transducer due to the copper mate-
rial of the transducer and of the piezoelectric element.
Fig. 4A shows the lesion depth (experimental and simulated) as
a function of time in vitro heart using acoustic power of 6 W. The
spacing between the transducer and the heart tissue was 1 mm.
The agreement between experimental and simulated results is
excellent. Fig. 4B shows the lesion depth (experimental and simu-
lated) as a function of power for a sonication duration of 35 s. The
spacing between the transducer and heart tissue was also 1 mm.
Based on the results of Fig. 4A it is concluded that in order to
achieve 15 mm depth with acoustic power of 6 W exposure dura-
tion of 60 s is needed. From Fig. 4B it can be shown that to create
a lesion of 15 mm 35 s are needed at a power of 9 W (Fig. 4B).
Fig. 5A shows a photograph of two lesions created in lamb heart
in vitro at a plane perpendicular to the transducer beam axis. The
power used was 6 W for 60 s. Note that the area of this lesion is
slightly above the transducer area which is 10  3 mm2. During
Table 1
Physical parameters used for simulations.
Parameter In vivo values
Heart Water
Thermal conductivity (Wm1 C1)* 0.537* 0.627
Specific heat (J kg1 C1)* 3720* 4188
Initial temperature (C)* 37 10
Perfusion (kg m3 s1)* 14.2* –
Density (kg m3)* 1060 1000
Attenuation (Np m1 MHz1)* 4.1* 0
* Values taken from Duck FA. Physical properties of tissue. A comprehensive ref-
erence book. New York: Academic Press, 1990.
gross anatomy the lesion depth was close to 15 mm. Fig. 5B shows
the MRI image of the result of Fig. 5A using T1-W FSE for TR of
500 ms. Note that the lesion appears much brighter than the heart
tissue, resulting to good image contrast. Fig. 5C shows the MRI im-
age of the result of Fig. 5A using T2-W FSE with TE of 80 ms. In the
T2-W image the lesion appears darker compared to the heart
tissue.
T1-W FSE was investigated further by using different TR (200–
1000 ms with increment step of 100 ms) and T2-W FSE was inves-
tigated further by using different TE (20, 40, 60, 100, and 120 ms).
Fig. 6A shows the contrast to noise ratio (CNR) of T1 FSE plotted
against TR in lamb heart in vitro. Fig. 6B shows the contrast to noise
Fig. 3. T1W FSE images of the 2 transducers utilized during the experiments in sagital (A) and coronal (B) planes.
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Fig. 4. (A) Depth of lesion (experimental and simulated) as a function of time
in vitro heart using acoustic power of 6 W. The spacing between the transducer and
heart tissue was 1 mm. (B), Depth of the lesion (experimental and simulated) as a
function of power for sonication duration of 35 s. The spacing between the
transducer and heart tissue was also 1 mm.
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Fig. 5. (A) Photograph in vitro of two lesions created in lamb heart in vitro at a plane
perpendicular to the transducer beam axis. The power used was 6 W for 60 s. (B).
MRI image of the result of figure A using T1-W FSE for TR of 500 ms. (C). MRI image
of the result of figure A using T2-W FSE with TE of 80 ms.
ratio (CNR) of T2-W FSE plotted against TE in lamb heart in vitro.
Note that the CNR with T2-W FSE is much lower than T1-W FSE.
Fig. 7A shows a photo of a lesion created in the heart of lamb
tissue in vitro using 7 W at 35 s. The shape and size is in very good
agreement with the lesion predicted by the simulation model
(Fig. 7B). The experimental lesion depth was 10 mm, whereas the
simulated lesion depth was 9.5 mm.
Fig. 8 shows a photo of a lesion created in the heart of rabbit
in vivo using 7 W for 35 s. The area of the lesion in a plane parallel
to the transducer follows the area of the transducer (3  10 mm2).
Despite of the motion of the heart and the high perfusion in the
heart, it was feasible to obtained lesion size similar to what was
obtain in the in vitro case (3  10 mm2), however the penetration
depth in the tissue was 12 mm compared to 15 mm (in vitro case).
The thickness of this particular heart was 19 mm. The lesion was
measured after the animal was sacrificed using a digital calliper.
Lastly, Fig. 9 shows the simulated depth vs. time at various lev-
els of acoustic power. This figure essentially shows the main out-
come of this study in one graph. It shows transducer (lesion
depth) vs. the two main user-selected parameters (power and
time). Note that the higher the power, the higher the rate of in-
crease of lesion depth with time.
Fig. 10 shows the lesion depth created by the transducer using
6 W for 60 s for the various in vivo experiments. The mean lesion
depth (excluding 2 experiments that failed due to possibly bad
coupling) was 11.93 mm with a standard deviation of 0.62 mm.
4. Discussion
This paper presents a flat rectangular MR compatible transducer
which can be used in the future to treat arrhythmias. This trans-
ducer was evaluated in lamb heart in vitro and in rabbit heart
in vivo. A major part of the paper was to evaluate the performance
of this transducer using a thermal simulation model. In this study,
it is shown that the experimental and simulated results are in rea-
sonable agreement, indicating that the theoretical model can be
used to give guidelines for this type of transducer.
The target of this study was to create lesions of depth of at least
15 mm. This depth is sufficient to destroy unwanted electrical sig-
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Fig. 6. (A) Contrast to noise ratio (CNR) of T1 FSE plotted against TR in lamb heart
in vitro. (B). Contrast to noise ratio (CNR) of T2-W FSE plotted against TE in lamb
heart in vitro.
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Fig. 7. (A). Photo of a lesion created in the heart of lamb tissue in vitro using 7 W for 35 s. (B). Simulated lesion for the exposure conditions of figure A.
Fig. 8. Photo of a lesion created in the heart of rabbit in vivo using 6 W at 120 s.
nals in the heart, and therefore treat arrhythmias. The size of
necrosis in a plane parallel to the transducer face is always slightly
higher than the transducer area (10  3 mm2). The depth of lesions
as expected increases with time, and the rate of increase of lesion
depth with respect to time is higher for higher power. With in-
creased acoustic power, the exposure duration needed to achieve
the same lesion dimensions deep in the tissue is decreased. In fu-
ture clinical trials, this transducer can be attached to a catheter,
and with MRI it will be easy to guide and monitor treatment.
MRI has the added advantage that offers a better contrast between
thermal necrosis and cardiac tissue than ultrasound or X-rays.
The size of the lesion in a plane parallel to the transducer face as
shown in Fig. 7A (experimental) or Fig. 7B (simulated) is
3  10 mm2 (corresponds to the area of the transducer). At a dee-
per level, the size of the lesion becomes smaller. This is attributed
to the fact that deeper in the tissue the intensity drops, and neces-
sarily so does the temperature. As a result, the lateral conduction
effect is lower and therefore the lesion size becomes smaller. If
one needs a deeper lesion, then either the power or time has to
be increased, taking care not to exceed temperatures above
100 C. Increased ablation time means increased treatment time,
however the ablation time (1 min per lesion) is low compared to
the time needed to place in future clinical trials a catheter in the
heart (30–60 min).
The transducer used produces lesions depth up to 15 mm. This
shows that with this therapeutic ultrasound technology, the lesion
size in cardiac tissue is larger than the lesions created with other
ablation techniques, such as radio frequency [13]. We have chosen
a transducer operating at the frequency of 5 MHz although a higher
frequency transducer could be more beneficial [17]. Since this
catheter is inserted in the body (i.e. it is consumable) going to high-
er frequency means a more expensive transducer. We use 5 MHz
which is not very expensive and as we have proved the efficacy
is not harmed.
There are many studies that predicted the size of the lesions as
function of power and time (for example [54,56,57]). For example
Damianou and Hynynen [56] evaluated the lesion size in dog mus-
cle in vitro, Fagi et al. [57] performed a similar study in bovine in
liver and Curiel et al. [54] have evaluated the lesion size in pros-
tate. Therefore, for each application (in our case heart) and for
every transducer (in our case planar) the lesion size has to be eval-
uated both using simulation and experimental models. This para-
metric information is very essential because when this
technology is applied to humans the users should have an indica-
tive knowledge of the lesion size.
The effect of perfusion is important especially using such long
time duration (60 s). For example for 6 W and 60 s duration the
in vitro experiments the depth of lesion is approximately 15 mm.
Using the same exposure in vivo, the depth of lesion is 12 mm
which is attributed to the perfusion effect [58].
In this paper the other major goal was to measure the CNR of
FSE MRI sequences in detecting thermal lesions created by thera-
peutic ultrasound in heart. Both T1-W FSE and T2-W FSE have been
proven successful for providing excellent contrast between rabbit
heart and thermal lesion. The maximum contrast measured with
T1-W FSE is approximately 22. With T1-W FSE the TR under which
CNR is maximized is between 300 ms and 800 ms.
The trend of CNR vs. TR starts to increase then it becomes flat
and then at high TRs it starts to decrease again. This trend is justi-
fied because at low TRs, the difference between signal intensity of
lesion and tissue is low at short times and therefore CNR is lower.
At higher TR the signal intensity of lesion and tissue reaches their
maxima and therefore the signal difference is lower and hence the
CNR drops again.
The maximum CNR measured with T2-W FSE is 13. With T2-W
FSE the TE under which CNR is maximized is between 30 and
60 ms. The trend of CNR vs. TE starts to increase then it becomes
flat and then at high TEs it starts to decrease again. The same
explanation holds as in the case of T1-W FSE.
The cost of this prototype research unit (transducer, cabling and
tubing for cooling) is approximately 1500 Euros. If the transducer,
cabling and tubing for cooling are produced as a final product for
clinical use in large quantities the cost could be close to 600 Euros.
This figure puts the HIFU ablation catheter at a cost which is about
20% more expensive than the RF ablation catheter.
We still believe that with the use of MRI the treatment of
arrhythmias has a clinical use (despite the complication mentioned
Fig. 9. Simulated depth vs. time at various levels of acoustic power.
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Fig. 10. Lesion depth created by the transducer using 6 W for 30 s for the various
in vivo experiments. The mean lesion depth was 12.93 mm (standard deviation was
0.62 mm.
by Metzner et al. 2010 [42]), because with the near real time imag-
ing, the result of the therapy can be monitored. Therefore it is too
early to abandon this technology for treating arrhythmias. Maybe
in the future we may come to the conclusion that MRI cannot mon-
itor the heating effects in the beating heart precisely, however this
must be determined in future MRI studies.
4.1. Future work
In vitro MRI experiments do not provide much value due to the
fact that the MRI response of a living tissue is different from ex vivo
tissue responses. Thus, more in vivowork has to be done, especially
regarding the MRI evaluation of thermal lesions. Additional MRI
routines have to be explored because the FSE sequences used are
long and sensitive to motion and could not be the optimum rou-
tines in a beating heart.
The key advantage of MRI is its ability to map temperature.
However, this is difficult in a beating heart. In this paper there
was no attempt to map the temperature in the heart tissue using
MRI, and therefore this a key future task.
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